Soleno Stock (SLNO) Soars 32% after FDA Greenlights New Drug
Soleno Therapeutics (SLNO) stock jumped over 32% in yesterday’s after-hours trading. The surge came after the company ...
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval
Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...
Soleno Therapeutics (SLNO) Receives a Buy from Piper Sandler
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Soleno Therapeutics (SLNO – Research Report) today and set a price target of ...
TipRanks on MSN3d
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment
Soleno Therapeutics ($SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone ...
STAT6d
NIH director targets misinformation research as more turmoil rocks health agencies
Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...
Tiny Silicon Valley drugmaker soars on FDA win to treat never-ending hunger
Shares of the Redwood City-based Soleno Therapeutics climbed 38% — the biggest one-day gain since September 2023 — to their ...
Explore more
Investor's Business Daily on MSN5d
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
Soleno Therapeutics won approval for a drug that treats excessive hunger associated with a rare disease, and the biotech ...
STAT6d
Soleno Therapeutics’ ‘life-changing’ rare-disease drug approved
The FDA Wednesday approved the first drug to treat people with Prader-Willi syndrome, a rare genetic disease that causes an ...
Soleno Therapeutics (NASDAQ:SLNO) Sees Strong Trading Volume Following Analyst Upgrade
Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) saw unusually-high trading volume on Monday after HC ...
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options
Shares of Soleno Therapeutics jumped 40% in morning trading on Thursday, after the company's drug for a rare metabolic condition became the first such treatment to receive U.S. regulatory nod.
US FDA approves first treatment for rare genetic disorder Prader-Willi syndrome
The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic disorder, ...
American Association of Individual Investors5d
Why Soleno Therapeutics, Inc.’s (SLNO) Stock Is Up 35.80%
Soleno Therapeutics, Inc.’s SLNO share price has surged by 35.80%, which has investors questioning if this is right time to ...